Pharma Mar SA · BME:PHM
Pharma Mar SA — Investor Presentation (November 2022)
34 slides from Pharma Mar SA's investor presentation, November 2022
Slide 1: Corporate Presentation
November 2022 Corporate Presentation World leader in the development and commercialization of anticancer drugs of marine origin
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity, results of operation, clinical program, plans and objectives of Pharma Mar, S.A. ("PharmaMar" or the "Company"). These f
Slide 3: Management Team
Management Team We are inspired by the sea, driven by science, and motivated to improve the lives of cancer patients by delivering novel medicines. We intend to continue to be the world leader in marine D. José María Fernández, Ph.D Luis Mora medicinal discovery, development and Chief Executive Offi
Slide 4: Corporate Overview
Corporate Overview Global Fully Integrated 3 Approved Oncology Commercial Stage Biotech Products Developing marine-inspired oncology drugs Established European oncology sales force Revenue Generating & Profitable Discovery Platform Strengthening Oncology Revenues in 2021 €230m Pipeline EBITDA 2021 €
Slide 5: The Plan for Growth
The Plan for Growth On Track to Deliver Value to Shareholders Lurbinectedin Other drugs Corporate development development development ✦ Phase 3 trial with Lurbinectedin ✦ Looking for in-licensing products ✦ 2 Phase 2 trials for Ecubectedin to market in EU in SCLC for EU approval enrolling and confir
Slide 6: Pipeline – Expanding our Expertise in Oncology
Pipeline – Expanding our Expertise in Oncology Phase 1 Phase 2 Phase 3 Market Soft tissue sarcoma 2nd/3rd line Monotherapy Ovarian cancer 2nd/3rd line + Doxil (PLD) R/R Multiple Myeloma1 3rd/4th line + dexamethasone Small cell lung cancer 2nd line US Monotherapy Small cell lung cancer Maintenance +
Slide 7: Lurbinectedin - Novel Selective Inhibitor of Oncogenic Transcription
Lurbinectedin - Novel Selective Inhibitor of Oncogenic Transcription Lurbinectedin binds preferentially within Transcription the promoter area of a selected group of Factors genes, in triplets: Lurbinectedin SWI/SNF SWI/SNF ARID1A ARID1A DNA RNA Pol II 5’-AGC-3’ 5’-CGG-3’ 5’-TGG-3’ 5’-AGG-3’ Harlow
Slide 8: Lurbinectedin – Effects on the Immune System
Lurbinectedin – Effects on the Immune System Lurbinectedin depletes the presence of TAMs in the tumor and inhibits the production of certain protumoral chemokines by them IL-6 TAMs VEGF IL-8 IL-8 CCL2 Inhibition of Tumor Cell IL-6 Induction of Proliferation angiogenesis Inhibition of Immune Response
Slide 9: 1st FDA approved drug in over 24 years for relapsed SCLC
SCLC 1st FDA approved drug in over 24 years for Relapsed Small Cell Lung Cancer (SCLC) New Standard of Care in 2L SCLC in the US 9
Slide 10: Zepzelca: Transformative for PharmaMar
Zepzelca: Transformative for PharmaMar License agreement in the US/Canada $200m received upfront ✦ 2021 sales = $46m royalties for PharmaMar $100m received approval ✦ High teens to 30% Royalties on US/Canada sales $25m received commercial milestone ✦ Initiated Phase 3 in 1L maintenance ES-SCLC in co
Slide 11: Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC) SCLC An Underserved High Unmet Medical Need Among all Lung Cancers Low survival rate at 5 years Limited treatment options in both the US and Europe SCLC 15% ✦ Highly aggressive tumor 61,300 in 20182 ✦ 5-year survival rate 5-10%1 30,000 in 20182 Newly diagnosed patients
Slide 12: Development Lagging Behind NSCLC
Small Cell Lung Cancer (SCLC) SCLC Development Lagging Behind NSCLC 1st Line Cisplatin + Carboplatin + Durv or Atezo + Etoposide Etoposide Carboplatin + SCLC Etoposide 2nd Line Topotecan Pre - 1993 1996 24 years 2020 NSCLC 12
Slide 13: Zepzelca – The SCLC Treatment Paradigm
Zepzelca (Lurbinectedin) – The SCLC Treatment Paradigm SCLC Strong Positioning Opportunity 1st Line 2nd Line 3rd Line 1st Line 2nd Line 3rd Line • Platinum/ • Platinum/ Etoposide + • Zepzelca Etoposide + FDA EMA • Topotecan • Topotecan Approved • Atezolizumab Approved • Atezolizumab or Durvalumab (s
Slide 14: Zepzelca Already Treatment of Choice in 2L SCLC
Zepzelca Already Treatment of Choice in 2L SCLC SCLC With Significant Room to Grow Other; 4% I/O; 14% 37% % Market Share in 2L SCLC in the US 40 37% Topotecan; 8% 33 Non-platinum 25 Chemo; 9% 18 Platinum retreatment; 10 28% Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 1. Adapted from Jazz Pharmaceuticals
Slide 15: Zepzelca Demonstrated Efficacy in Sensitive and Resistant SCLC
Zepzelca Demonstrated Efficacy in Sensitive and Resistant SCLC Small Cell Lung Cancer patients In relapsed SCLC as monotherapy under accelerated approval based on Phase 2 monotherapy data1 Overall Resistant Sensitive Decrease in tumor size in 65% patients2 (n=105) CTFI< 90 days CTFI= 90 days (n=45)
Slide 16: Low Rate of AEs and Manageable Hematological Safety Profile
Zepzelca Already Treatment of Choice in 2L SCLC SCLC Low Rate of AEs and Manageable Hematological Safety Profile Despite Low Use of G-CSF 1,2 Safety: Related or Unknown Treatment Related (or Unknown) Adverse Events Adverse Events (AEs) ( >5% or Gr 3-4) Overall (n=105) n (%) Gr 1-2 Gr 3-4 Overall (n=
Slide 17: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA
Zepzelca: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA Phase 3 (LAGOON) randomized trial Arm A Lurbinectedin 3.2 mg/m2 every 3 weeks Primary Endpoint: ✦ Relapsed SCLC Arm B ✦ One prior platinum Randomization Overall Survival containing regimen 1:1:1 Arm A vs. C ✦ CTFI ≥30 days 705 pat
Slide 18: 1st line-Maintenance Study in SCLC
SCLC 1st line-Maintenance Study in SCLC 18
Slide 19: Lurbinectedin-Atezolizumab combo in relapsed SCLC (PoC trial)
Lurbinectedin-Atezolizumab combo in relapsed SCLC (PoC trial) • Phase I open label dose ranging trial in pts who had progressed on platinum. ECOG 0-1 • Full dose Atezo + L2.5mg/m2 (n=5) followed by L3.2mg/m2 (n=21, full dose) Response N=26 CR 8% (2) PR 50% (13) ORR 58% (15) SD 27% (6) DCR 85% PD 12%
Slide 20: Lurbinectedin: First line positioning
Lurbinectedin: First line positioning SCLC Phase 3 IMforte trial for First line-Maintenance SCLC Induction Phase Maintenance Phase Atezolizumab 1,200 mg q3wk + Lurbinectedin 3.2 mg/m2 q3wk ✦ Extensive-stage Endpoints: SCLC (ES-SCLC) Atezolizumab + Randomization ✦ Ongoing response Carboplatin + 1:1 ✦
Slide 21: Strategic importance of Zepzelca Phase 3s in SCLC
Strategic importance of Zepzelca Phase 3s in SCLC Potential treatment landscape after Phase 3s SCLC 1st Line- 1st Line- 1st Line 2nd Line 1st Line 2nd Line Mantenance Mantenance ✦ Platinum/ ✦ Platinum/ Etoposide + ✦Zepzelca ✦ Zepzelca Etoposide + ✦ Zepzelca + • Zepzelca FDA ✦ Topotecan EMA • Topotec
Slide 22: Malignant Pleural Mesothelioma Finalizing Trial Strategy
MPM Malignant Pleural Mesothelioma Finalizing Trial Strategy 22
Slide 23: Zepzelca – Relapsed Malignant Pleural Mesothelioma
Zepzelca (Lurbinectedin) – Relapsed Malignant Pleural Mesothelioma MPM A Rare Disease with limited available Therapeutic Options Aggressively growing tumor ~ 80% of cases related to asbestos exposure Incidence ~3,0001 patients diagnosed in the US per year Incidence and ~11,000 in Europe2 1st Line 2n
Slide 24: Zepzelca – PFS Benefit in Malignant Pleural Mesothelioma
Zepzelca (Lurbinectedin) – PFS Benefit in Malignant Pleural Mesothelioma Phase 2 Study1 MPM ✦ Primary endpoint PFS at 12 ✦ 42 patients progression weeks: on 1 prior platinum based ✦ Primary endpoint met therapy (p=0.015) Planning Phase 3 ✦ Lurbinectedin at 3.2 mg/m 2 ✦ mPFS 4.1 months every 3 weeks
Slide 25: Leveraging Commercial Infrastructure in Europe
European experience: Leveraging Commercial Infrastructure in Europe ✦ Strong KOL connections in solid tumors PharmaMar positioned as a partner of choice in Europe ✦ Navigation of EU, UK and CH regulators ✦ Logistics in place for distribution ✦ Expertise in multi-language labelling 18 Regional Partne
Slide 26: Zepzelca (Lurbinectedin) – Intellectual property
Zepzelca (Lurbinectedin) – Intellectual property Life cycle management plans under way 2022 2023 2024 2025 2026 2027 2028+ Orphan Drug Exclusivity in SCLC New Chemical Entity Composition of Matter Patent Potential 5 year extension to 2029 (filed) Orphan Drug Exclusivity in SCLC Composition of Matter
Slide 27: Other opportunities
Other opportunities 27
Slide 28: Plitidepsin in SARS-CoV-2 Patients
Plitidepsin in SARS-CoV-2 Patients ✦ SARS-CoV-2 cells co-opt EF1A from host to replicate ✦ Positive multi-center clinical trial ✦ Safety primary endpoint met for 3 doses ✦ Viral load and CRP reduced ✦ Pivotal Phase 3 ongoing (Neptuno / NCT04784559) 5nM plitidepsin HCoV-229E infected cells 1. Sources
Slide 29: Plitidepsin in SARS-CoV-2 Patients: Phase 3 Study NEPTUNO 1
Plitidepsin in SARS-CoV-2 Patients: Phase 3 Study NEPTUNO1 Adult Patients with Moderate Disease Hospitalized moderate COVID-19 adult pts requiring O2 supplementation n=203 plitidepsin 2.5mg IV per day dexamethasone 6mg/day patients + dexamethasone 8mg/day Primary endpoint: Time until n=203 plitideps
Slide 30: Financials
Financials Pharma May
Slide 31: Financials
Financials Well financed to support next stages of development Robust Cash Position (€m) Profitable (€m) 300 300 225 225 150 150 75 75 0 0 (75) (150) (75) 2018 2019 2020 2021 2018 2019 2020 2021 Debt Cash Revenues EBITDA 31
Slide 32: Key Events
Key Events Catalyst Calendar Lurbi Combo Atezo data presented at SITC Zepzelca approved in additional countries UAE, Singapore, Australia, Canada 2nd line Phase 3 SCLC trial initiation Ecubectedin “First Patient In” Phase 2 Potential first Zepzelca sales milestone Potential lurbinectedin approvals i
Slide 33: Building the Next Phase of Growth
Building the Next Phase of Growth 2021-2026 Strong Zepzelca Leveraging proven oncology drugs Intellectual in new indications and expanding Property into new territories Zepzelca expected Clinical data Solid financial capabilities to new approvals and launches in non-EMA IP 2022-25 broaden and accele
Slide 34: www.pharmamar.com
www.pharmamar.com. . a Dy i - 3 aA > = = aS - ae! ~